Matched groups were found to be balanced except for N stage ( more N3 disease in SD ) , median treatment year ( SD in 2003 ; ID in 2007 ) , platinum and taxane chemotherapy ( SD in 28 % ; ID in 39 % ) , and median follow-up ( SD were 89 months ; ID were 40 months ) .